IsraelTuberculosis profile
Population  2016 8.2 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.015 (0.015–0.016) 0.19 (0.18–0.19)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.04 (0.03–0.05)
Incidence  (includes HIV+TB) 0.29 (0.25–0.33) 3.5 (3–4.1)
Incidence (HIV+TB only) 0.021 (0.013–0.03) 0.25 (0.16–0.36)
Incidence (MDR/RR-TB)** 0.024 (0.011–0.038) 0.3 (0.13–0.46)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.011 (<0.01–0.012) 0.085 (0.072–0.098) 0.096 (0.081–0.11)
Males 0.011 (<0.01–0.013) 0.18 (0.15–0.21) 0.19 (0.16–0.22)
Total 0.022 (0.018–0.025) 0.27 (0.23–0.31) 0.29 (0.25–0.33)
TB case notifications, 2016  
Total cases notified 250
Total new and relapse 250
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 72%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.06–0.08)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 18 7%
          - on antiretroviral therapy 16 89%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  13
(5–22)
Estimated % of TB cases with MDR/RR-TB 7.4% (3.5–14) 0% (0–84)  
% notified tested for rifampicin resistance 63% 25% 154
MDR/RR-TB cases tested for resistance to second-line drugs   11
Laboratory-confirmed cases MDR/RR-TB: 11, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 11, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 83% 263
Previously treated cases, excluding relapse, registered in 2015   0
HIV-positive TB cases registered in 2015 71% 14
MDR/RR-TB cases started on second-line treatment in 2014 75% 16
XDR-TB cases started on second-line treatment in 2014 50% 2
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data